Genezen receives growth equity investment from Ampersand Capital Partners

Scroll Down

Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production, and analytical testing services, today announced a majority investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector. Ampersand’s investment will be used to complete the construction of the company’s 25,000 square foot cGMP-compliant lentiviral vector production facility, which will also offer a full suite of process development and analytical capabilities.

Read the full press release here.

You may also be interested in...

Genezen Appoints Vice President of Quality…

Genezen Inc., a cell and gene therapy Contract Development and Manufacturing...

Read more

Suspension platform development for lentiviral vector…

Development of a Transfection-based, Scalable, Serum-Free, Single-Use Suspension Platform for Manufacturing...

Read more

Get to know Genezen

Watch now Genezen is dedicated to exceptional gene and cell therapy....

Read more

Genezen Appoints New CEO as GMP…

Genezen Inc., a cell and gene therapy Contract Development and Manufacturing...

Read more